

12th November, 2024

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001.

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra Kurla Complex, Bandra (East), Mumbai
400 051.

Script Code: 500259

Script Code: LYKALABS

Dear Sir/Madam,

Sub.: Statement of deviation or variation for the quarter ended 30th September 2024 of funds raised through Preferential Issue of Equity Share Warrants

Ref.: Disclosure in terms of Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the SEBI Listing Regulations)

Pursuant to Regulation 32 of the SEBI Listing Regulations read with SEBI Circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13th July, 2023 regarding 'Statement of Deviation or Variation for proceeds of public issue, rights issue, preferential issue, Qualified Institutions Placement (QIP) etc', the Company hereby confirms that there has been no deviation(s) or variation(s) in the use of the proceeds raised from Preferential issue of Convertible warrants into Equity Shares.

A NIL statement of deviation or variation duly reviewed by the Audit Committee and taken on record by the Board at their respective meetings held on today i.e. 12th November, 2024 is enclosed herewith as **Annexure A**.

Further, this is to inform you that the funds raised from the issue of the securities has been fully utilised to strengthen the Company's overall financial structure by augmentation of long-term financial resources and corresponding reduction of debt through repayment of loans and for meeting working capital requirements and for other general corporate purposes. Therefore, the filing of statement of deviation or variation under Regulation 32 the SEBI Listing Regulations will be no longer applicable to the Company from here onwards.

We request you to take the same on record.

Thanking You,

Yours faithfully,

For **Lyka Labs Limited**

Kunal Gandhi
Managing Director

DIN: 01516156

Encl.: as above

Annexure -A

Statement of Deviation/ Variation						
Name of listed entity	Lyka Labs Limited					
Mode of Fund Raising	Preferential Alloment					
Type of instrument	Warrants convertible Equity Shares					
Date of Raising Funds	16th April, 2024					
Amount Raised (Rs. In Crores)	Rs.27.2025 Crores (75% of the issuee price of Rs.139.50 per such warrant)					
Report filed for quarter ended	30th Sep 2024					
Is there a Deviation / Variation in use of funds raised ?	No					
Whether any approval is required to vary the objects of the issue stated in the prospectus/ offer document?	No					
If yes, details of the approval so required?	Not Applicable					
Date of approval	Not Applicable					
Explanation for the Deviation / Variation	Not Applicable					
Comments of the Audit Committee after review	The Audit Committee has noted that there was no deviation/ variation in the use of funds raised by issue of Equity Shares and Warrants convertible into Equity Shares, both on preferential basis and the funds raised from the issue of the securities has been fully utilised to strengthen the Company's overall financial structure by augmentation of long-term financial resources					
Comments of the Auditors, if any	Not Applicable					
Objects for which funds have been raised and where there has been a deviation, in the following table	Not Applicable					
Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation / Variation for the half year according to applicable object (INR Crores and in%)	Remarks, if any
The funds to be raised from the proposed issue of securities will be utilised to strengthen the Company's overall financial structure by augmentation of long-term financial resources and corresponding reduction of debt through repayment of loans and for meeting working capital requirements and for other general corporate purposes.	Not Applicable	Rs.27.2025 Crores	Not Applicable	Rs.27.2025 Crores	Not Applicable	No Deviation

Deviation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised
 (b) Deviation in the amount of funds actually utilized as against what was originally disclosed.

For Lyka Labs Limited


 Yogesh Shah

Executive Director & CFO
 DIN: 06396150

Mumbai, 12th November, 2024

